In 2018, a kind of HSA nanoparticles loaded with paclitaxel was constructed for the targeted therapy of glioma by Ruan et al., and this kind of albumin nanoparticles can effectively cross the blood–brain barrier to target brain capillary endothelial cells and U87 cells. This evidence concerns the gene ALB and central nervous system cancer.